Solventum Corp Files 8-K on Officer Changes and Financials

TL;DR

Solventum Corp 8-K filed: Officer changes, director elections, and financial statements are on the docket.

AI Summary

Solventum Corporation, formerly 3M Health Care Co, filed an 8-K on November 5, 2024, reporting events as of October 30, 2024. The filing pertains to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. It also includes financial statements and exhibits.

Why It Matters

This filing provides crucial updates on the corporate governance and financial reporting of Solventum Corporation, impacting investor understanding of its leadership and financial health.

Risk Assessment

Risk Level: low — This is a routine corporate filing detailing officer and director changes and financial statements, not indicating any immediate operational or financial distress.

Key Players & Entities

• Solventum Corporation (company) — Registrant
• 3M Health Care Co (company) — Former company name
• 3M Company (company) — Associated company
• October 30, 2024 (date) — Earliest event reported
• November 5, 2024 (date) — Date of report

FAQ

From the Filing

0001964738-24-000036.txt : 20241105 0001964738-24-000036.hdr.sgml : 20241105 20241105161145 ACCESSION NUMBER: 0001964738-24-000036 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 29 CONFORMED PERIOD OF REPORT: 20241030 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241105 DATE AS OF CHANGE: 20241105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Solventum Corp CENTRAL INDEX KEY: 0001964738 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 922008841 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41968 FILM NUMBER: 241427584 BUSINESS ADDRESS: STREET 1: C/O 3M COMPANY STREET 2: 3M CENTER, BUILDING 275-6W-02 CITY: ST. PAUL STATE: MN ZIP: 55144-1000 BUSINESS PHONE: 651-733-1110 MAIL ADDRESS: STREET 1: C/O 3M COMPANY STREET 2: 3M CENTER, BUILDING 275-6W-02 CITY: ST. PAUL STATE: MN ZIP: 55144-1000 FORMER COMPANY: FORMER CONFORMED NAME: 3M Health Care Co DATE OF NAME CHANGE: 20230203 8-K 1 solv-20241030.htm 8-K solv-20241030 FALSE 0001964738 0001964738 2024-09-20 2024-09-20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 30, 2024      Solventum Corporation (Exact name of registrant as specified in its charter) Delaware 001-41968 92-2008841 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 3M Center, Building 275-6W 2510 Conway Avenue East Maplewood , MN 55144 (Address of Principal Executive Offices, including Zip code) ( 651 ) 733-1110 (Registrant’s telephone number, including area code) (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share SOLV New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 30, 2024, the Talent Committee of the Board of Directors (the “Committee”) of Solventum Corporation (“Solventum”) approved and adopted the Solventum Executive Change in Control Severance Plan (the “CIC Severance Plan”), which is effective as of such date. Solventum’s Chief Executive Officer (“CEO”), Chief Financial Officer, Chief Accounting Officer,